Progression Free Survival | ||
---|---|---|
Univariate Analysis | Multivariate Analysis | |
VARIABLE (Comparator) | HR (95% CI); p - value | HR (95% CI); p - value |
BMI ≥ 25 vs < 25 | 0.46 (0.39–0.54); p < 0.0001 | 0.71 (0.56–0.90); p < 0.0001 |
Weighta | 0.97 (0.96–0.98); p < 0.0001 | 0.99 (0.98–1.01); p = 0.1580 |
irAEs of any grade Yes vs No | 0.48 (0.41–0.57); p < 0.0001 | 0.67 (0.54–0.83); p = 0.0002 |
Primary Tumor (NSCLC) | ||
Melanoma | 0.52 (0.42–0.66); p < 0.0001 | 0.67 (0.53–0.85); p = 0.0008 |
Kidney | 0.72 (0.58–0.91); p = 0.0062 | 0.67 (0.53–0.84); p = 0.0008 |
Others | 1.08 (0.65–1.78); p = 0.7556 | 0.69 (0.41–1.15); p = 0.1533 |
Sex Male vs Female | 1.20 (1.01–1.42); p = 0.0314 | 1.03 (0.86–1.22); p = 0.7252 |
Age Elderly vs Non-elderly | 0.96 (0.82–1.12); p = 0.6394 | – |
Treatment line Non-first vs First | 1.62 (1.33–1.96); p < 0.0001 | 1.61 (1.32–1.93); p < 0.0001 |
N° of metastatic sites > 2 vs ≤ 2 | 1.46 (1.27–1.68); p < 0.0001 | 1.42 (1.21–1.67); p < 0.0001 |
ECOG PS ≥2 vs 0–1 | 2.60 (2.13–3.17); p < 0.0001 | 2.06 (1.67–2.52); p < 0.0001 |